GlassScriptPhysician profile
Robert C Nichols
NPI 1518942333
$2,605.54
in general payments reported to CMS, 2019-2025
27 companies · $196 in 2025
The $196 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $250 · 2021: $415 · 2022: $622 · 2023: $509 · 2024: $155 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $859.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,378.77 | 2019-2023 | Rybelsus, Ozempic |
| Lilly USA, LLC | $289.28 | 2022-2024 | Jardiance, Emgality, Mounjaro |
| Alexion Pharmaceuticals, INC. | $112.19 | 2022-2024 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $71.45 | 2019-2024 | Breztri |
| Abbott Laboratories | $68.18 | 2021-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $62.42 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Sanofi-Aventis U.S. LLC | $55.45 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.18 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $53.98 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Currax Pharmaceuticals LLC | $44.58 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $43.12 | 2023-2024 | Gemtesa |
| Amarin Pharma, INC. | $41.08 | 2019 | |
| Janssen Pharmaceuticals, INC | $40.41 | 2021-2023 | Xarelto |
| Pfizer INC. | $32.66 | 2021-2022 | |
| Vertex Pharmaceuticals Incorporated | $30.31 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalpropion Pharmaceuticals LLC | $28.94 | 2019 | |
| Aimmune Therapeutics, INC. | $28.72 | 2025 | Vowst |
| Genentech USA, INC. | $25.57 | 2019-2020 | |
| Sanofi Pasteur INC. | $24.56 | 2023 | |
| Seqirus USA INC | $20.15 | 2025 | Flucelvax, Fluad |
| Radius Health, INC. | $19.56 | 2019 | |
| Nestle Healthcare Nutrition INC. | $14.44 | 2021 | |
| Bioventus LLC | $14.09 | 2020 | |
| Vistapharm, INC. | $13.64 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.40 | 2019 | |
| Amgen INC. | $12.51 | 2019 | |
| Dynavax Technologies Corporation | $11.90 | 2024-2025 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Nichols listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.